Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 157

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 157
---
 its current cash on hand and access to existing financial arrangements will not be sufficient to fund its projected operating requirements for a period of one year from the issuance of these financial statements included elsewhere in this proxy statement/prospectus. This raises substantial doubt about its ability to continue as a going concern. NLS expects that it will require substantial additional capital to commercialize 42 its product candidates and put in place multiple options to raise the funds necessary to support its operations. However, its operating plans may change as a result of many factors that may currently be unknown to us, and NLS may need to seek additional funds sooner than planned. Its future funding requirements will depend on many factors, including but not limited to: •our clinical trial results and the costs for conducting pivotal trials; •the cost, timing and outcomes of seeking marketing approval of Quilience and/or Nolazol; •the cost of filing and prosecuting patent applications and the cost of defending NLS’s patents; •the cost of prosecuting patent infringement actions against third parties; •development of other early -stagedevelopment product candidates; •the costs associated with commercializing Quilience and/or Nolazol if NLS receives marketing approval, including the cost and timing of establishing sales and marketing capabilities to market and sell Quilience and/or Nolazol; •subject to receipt of marketing approval, revenue received from sales of approved products, if any, in the future; •any product liability or other lawsuits related to NLS’s products; •the expenses needed to attract and retain skilled personnel; and •the costs associated with being a public company. Any additional fundraising efforts may divert its management from their day -to-dayactivities, which may adversely affect its ability to develop and commercialize its product candidates. In addition, NLS cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of its securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of its NLS Common Shares or its publicly traded Warrants to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and NLS may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact its ability to